| Cash Flow | 2025-09-27 | 2025-06-28 |
|---|---|---|
| Net loss | -131,607 | -110,081 |
| Depreciation and amortization | 5,919 | 4,385 |
| Loss on equity investment | -1,566 | 394 |
| Stock-based compensation | 12,930 | 9,076 |
| Provision for inventory excess and obsolescence | 1,340 | 1,015 |
| Change in fair value of term loan | -1,079 | 2,687 |
| Debt issuance costs associated with warrants issued | 16,828 | - |
| Debt issuance costs expensed under fair value option | 0 | 16,828 |
| Deferred income taxes, net | -4,659 | -292 |
| Other | -4,600 | -3,112 |
| Accounts receivable | 4,814 | 3,735 |
| Inventory | 66,663 | 12,816 |
| Other assets | -5,815 | -5,700 |
| Accounts payable | 89,967 | 59,428 |
| Accrued expenses and other liabilities | -43,664 | -32,114 |
| Net cash used in operating activities | -104,203 | -56,617 |
| Additions of property and equipment | 0 | 0 |
| Purchase of investments | 14 | 14 |
| Sales and maturities of investments | -594 | - |
| Net cash provided by (used in) investing activities | 580 | -14 |
| Income tax withholding payment associated with restricted stock vesting | 371 | 257 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
| Repayment of term loan | 4,000 | 4,000 |
| Net cash used in financing activities | -4,371 | -4,257 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,856 | 1,914 |
| Net decrease in cash, cash equivalents and restricted cash | -106,138 | -58,974 |
| Cash and cash equivalents at beginning of period | 137,951 | - |
| Cash and cash equivalents at end of period | 31,813 | - |
IROBOT CORP (IRBT)
IROBOT CORP (IRBT)